Fulcrum Therapeutics (FULC) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to -$573.9 million.
- Fulcrum Therapeutics' Retained Earnings fell 1414.28% to -$573.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$573.9 million, marking a year-over-year decrease of 1414.28%. This contributed to the annual value of -$519.4 million for FY2024, which is 190.81% down from last year.
- Latest data reveals that Fulcrum Therapeutics reported Retained Earnings of -$573.9 million as of Q3 2025, which was down 1414.28% from -$554.3 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Retained Earnings registered a high of -$238.6 million during Q1 2021, and its lowest value of -$573.9 million during Q3 2025.
- Its 5-year average for Retained Earnings is -$429.8 million, with a median of -$460.9 million in 2023.
- Per our database at Business Quant, Fulcrum Therapeutics' Retained Earnings plummeted by 4098.36% in 2021 and then fell by 10.38% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' Retained Earnings (Quarter) stood at -$302.5 million in 2021, then tumbled by 36.31% to -$412.3 million in 2022, then fell by 23.61% to -$509.7 million in 2023, then dropped by 1.91% to -$519.4 million in 2024, then decreased by 10.5% to -$573.9 million in 2025.
- Its last three reported values are -$573.9 million in Q3 2025, -$554.3 million for Q2 2025, and -$537.1 million during Q1 2025.